1. Home
  2. HRMY vs CASH Comparison

HRMY vs CASH Comparison

Compare HRMY & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • CASH
  • Stock Information
  • Founded
  • HRMY 2017
  • CASH 1954
  • Country
  • HRMY United States
  • CASH United States
  • Employees
  • HRMY N/A
  • CASH N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • CASH Major Banks
  • Sector
  • HRMY Health Care
  • CASH Finance
  • Exchange
  • HRMY Nasdaq
  • CASH Nasdaq
  • Market Cap
  • HRMY 1.5B
  • CASH 1.7B
  • IPO Year
  • HRMY 2020
  • CASH N/A
  • Fundamental
  • Price
  • HRMY $31.40
  • CASH $68.41
  • Analyst Decision
  • HRMY Strong Buy
  • CASH Buy
  • Analyst Count
  • HRMY 9
  • CASH 2
  • Target Price
  • HRMY $50.44
  • CASH $91.00
  • AVG Volume (30 Days)
  • HRMY 912.0K
  • CASH 212.3K
  • Earning Date
  • HRMY 11-04-2025
  • CASH 10-21-2025
  • Dividend Yield
  • HRMY N/A
  • CASH 0.29%
  • EPS Growth
  • HRMY 50.44
  • CASH 18.89
  • EPS
  • HRMY 3.17
  • CASH 7.87
  • Revenue
  • HRMY $825,944,000.00
  • CASH $783,120,000.00
  • Revenue This Year
  • HRMY $20.68
  • CASH $10.53
  • Revenue Next Year
  • HRMY $15.93
  • CASH $4.75
  • P/E Ratio
  • HRMY $9.92
  • CASH $8.73
  • Revenue Growth
  • HRMY 21.13
  • CASH 10.14
  • 52 Week Low
  • HRMY $25.52
  • CASH $64.45
  • 52 Week High
  • HRMY $40.93
  • CASH $86.00
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 63.59
  • CASH 39.18
  • Support Level
  • HRMY $27.66
  • CASH $65.93
  • Resistance Level
  • HRMY $30.96
  • CASH $69.38
  • Average True Range (ATR)
  • HRMY 1.25
  • CASH 1.36
  • MACD
  • HRMY 0.54
  • CASH -0.10
  • Stochastic Oscillator
  • HRMY 92.89
  • CASH 36.05

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: